Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLMGet Free Report) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 10,800 shares, a drop of 50.5% from the December 15th total of 21,800 shares. Based on an average daily trading volume, of 309,200 shares, the short-interest ratio is currently 0.0 days. Currently, 1.6% of the company’s stock are sold short.

Institutional Trading of Apollomics

An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC boosted its stake in shares of Apollomics, Inc. (NASDAQ:APLMFree Report) by 247.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,259,117 shares of the company’s stock after buying an additional 896,316 shares during the period. Exchange Traded Concepts LLC owned approximately 1.41% of Apollomics worth $179,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 19.13% of the company’s stock.

Apollomics Stock Performance

APLM stock traded up $0.11 during mid-day trading on Wednesday, hitting $10.23. 204 shares of the company were exchanged, compared to its average volume of 25,152. The firm’s 50 day simple moving average is $10.29 and its 200 day simple moving average is $13.55. Apollomics has a 1-year low of $6.50 and a 1-year high of $105.00.

Apollomics Company Profile

(Get Free Report)

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.

Featured Articles

Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.